LGND

#1394
Ligand Pharmaceuticals Inc.
231.2650 USD
+8.35%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
225.8000
231.4350
Faixa anual
175.8900
231.4350
Mudança diária
+8.35%
Mudança mensal
+13.20%
Mudança em 6 meses
+23.59%
Mudança anual
+23.59%
Fechamento anterior
213.4400
Abrir
230.0000
Bid
Ask
Mínimo
225.8000
High
231.4350
Volume
91
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 4.6117 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
30.84
Price to sales ratio
14.31
Dividends per share
2.5
Dividend yield %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Notícias